<DOC>
	<DOCNO>NCT02629627</DOCNO>
	<brief_summary>In Mexico , obesity major public health problem . In recent year present considerable increase population . As result , trigger proportional increase incidence cardiovascular disease development Metabolic Syndrome ( METS ) . Abdominal obesity one main component METS generally associate insulin resistance / hyperinsulinemia . This influence subcutaneous adipose tissue visceral adipose tissue . There evidence visceral fat important bearing many factor METS , like : glucose intolerance , hypertension , dyslipidemia , insulin resistance . For management require multidisciplinary approach , include change lifestyle , psychological nutritional intervention well pharmacological non-pharmacological support . Among non-pharmacological therapy , recently use Conjugated Linoleic Acid ( ACL ) leucine assign property include weight reduction , anti-atherogenic , hypocholesterolemic immunostimulant effect anticarcinogenic property . Regarding weight reduction dominate mechanism action anti-lipolytic effect . But , study need link consumption increase decrease visceral fat individual METS .</brief_summary>
	<brief_title>Conjugated Linoleic Acid / Leucine Versus Metformin Visceral Fat Metabolic Syndrome</brief_title>
	<detailed_description>The main objective compare effect administration ACL/Leucine vs. Metformin visceral fat area patient METS . We conduct double-blind trial , randomize , 4 group , group 26 male female patient 35-65 year age METS diagnose IDF criterion . Randomization determine receive intervention 8 week trial , group like : Group ( A ) intervention ACL/Leucine plus Metformin : 26 individual receive ACL/Leucine dosis 2,475mg per 24 hr ( 1,650mg 2 capsule first meal 825 mg 1 capsule second meal ) plus Metformin dose 500 mg per day ( first bite second meal ) 8 week . Group ( B ) Metformin plus Placebo ACL/Leucine : 26 individual receive Metformin dose 500 mg per day ( first bite second meal ) plus homologue placebo ACL/Leucine ( linseed oil capsule ) dosis 3600 mg 24 hr ( 2 capsule 2400 mg first meal 1200 mg 1 capsule second meal ) 8 week . Group ( C ) ACL/Leucine plus Metformin 's Placebo : 26 individual receive ACL/Leucine dose 2,475mg per 24 hr ( 1,650mg 2 capsule first meal 825 mg 1 capsule second meal ) plus homologate placebo metformin ( calcined magnesia ) dose 500 mg per day ( first bite second meal ) 8 week . Group ( D ) Placebo ACL/Leucine plus Placebo Metformin : homologate placebo ACL/Leucine ( linseed oil capsule ) dose 3600 mg 24 hr ( 2 capsule 2400 mg first meal 1200 mg 1 capsule second meal ) plus homologated placebo metformin ( calcine magnesia capsule ) dosis 500 mg per day ( first bite second meal ) 8 week . The clinical finding laboratory test include metabolic profile biosafety , baseline 8 week . Visceral fat area , epicardial fat , body weight , body fat , body mass index ( BMI ) blood pressure determine inicial final visit , likewise , hemodynamics parameter arterial stiffness like aortic pulse wave velocity ( PWVao ) , central pulse pressure ( PPao ) , aortic augmentation index ( IAxao ) central systolic blood pressure ( cSBP ) oscillometric monitor system via BPLab ® . Adverse event adherence treatment document . Statistical analysis : Mann-Whitney U Test Wilcoxon exact test . It consider significance p &lt; 0.05 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>Diagnosis metabolic syndrome IDF criterion : Central obesity ( defi ned waist circumference* ethnicity specifi c value ) ≥80 cm female ≥90 cm male plus two follow four factor : Raised triglyceride ≥ 150 mg/dL ( 1.7 mmol/L ) specific treatment lipid abnormality Reduced HDL colesterol &lt; 40 mg/dL ( 1.03 mmol/L ) males &lt; 50 mg/dL ( 1.29 mmol/L ) females specifi c treatment lipid abnormality Raised blood pressure systolic BP ≥ 130 diastolic BP ≥ 85 mm Hg treatment previously diagnose hypertension Raised fast plasma glucose ( FPG ) ≥ 100 mg/dL ( 5.6 mmol/L ) , previously diagnose type 2 diabetes Stable body weight last 3 month Written inform consent Ascitis With previous abdominal surgery Pathologies course abdominal wall edema fluid retention Paniculitis reumatic origin ethiology Reumatic pathology Metalic prothesis Previous know allergy ingredient make active treatment assign Known problem fat absortion , esteatorrea , lipase deficiency , malabsortion intestinal problem , CUCI</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Conjugated Linoleic Acid</keyword>
	<keyword>Leucine</keyword>
	<keyword>visceral fat area</keyword>
	<keyword>Epicardial Fat</keyword>
	<keyword>Hemodinamic Parameters</keyword>
</DOC>